Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
stocks
Overvalued ASX share has overly ambitious profit target
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.30 | 168.10 | -1.83% |
| CAC 40 | 8,216.78 | 135.22 | -1.62% |
| DAX 40 | 26,045.37 | 553.27 | -2.08% |
| Dow JONES (US) | 50,759.42 | 848.75 | -1.64% |
| FTSE 100 | 10,689.87 | 191.68 | -1.76% |
| HKSE | 23,508.17 | 245.67 | -1.03% |
| NASDAQ | 24,328.38 | 181.38 | -0.74% |
| Nikkei 225 | 58,860.43 | 801.59 | -1.34% |
| NZX 50 Index | 14,348.64 | 41.68 | 0.29% |
| S&P 500 | 7,340.53 | 76.06 | -1.03% |
| S&P/ASX 200 | 8,883.20 | 161.50 | -1.79% |
| SSE Composite Index | 3,584.58 | 17.99 | -0.50% |